CABA
Price
$1.52
Change
-$0.02 (-1.30%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
261.1M
18 days until earnings call
Intraday BUY SELL Signals
GHRS
Price
$18.47
Change
-$0.44 (-2.33%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
1.3B
14 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CABA vs GHRS

CABA vs GHRS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CABA vs. GHRS commentary
Oct 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CABA is a Hold and GHRS is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CABA with price predictions
Oct 21, 2026

CABA in -12.96% downward trend, sliding for three consecutive days on October 16, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CABA declined for three days, in 284 of 316 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day moving average for CABA crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.

The Aroon Indicator for CABA entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CABA's RSI Oscillator exited the oversold zone, 24 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +14.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where CABA advanced for three days, in 221 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

CABA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.240) is normal, around the industry mean (2.988). P/E Ratio (-1.116) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. CABA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CABA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for GHRS with price predictions
Oct 21, 2026

GHRS in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 23, 2026

GHRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 23 of 25 cases where GHRS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GHRS's RSI Oscillator exited the oversold zone, 16 of 18 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where GHRS advanced for three days, in 256 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GHRS as a result. In 85 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

The Moving Average Convergence Divergence Histogram (MACD) for GHRS turned negative on September 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 37 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.

GHRS moved below its 50-day moving average on September 18, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GHRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for GHRS entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.611) is normal, around the industry mean (2.988). P/E Ratio (-19.101) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. GHRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
CABA: Fundamental Ratings
CABA
OUTLOOK RATING
1..100
51
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
89
P/E GROWTH RATING
1..100
11
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CABAGHRS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
89%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 9 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
85%
COMPARISON
Comparison
Oct 22, 2026
Stock price -- (CABA: $1.54 vs. GHRS: $18.91)
Brand notoriety: CABA and GHRS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CABA: 56% vs. GHRS: 168%
Market capitalization -- CABA: $261.1M vs. GHRS: $1.3B
CABA [@Biotechnology] is valued at $261.1M. GHRS’s [@Biotechnology] market capitalization is $1.3B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.95B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CABA’s FA Score shows that 1 FA rating(s) are green while GHRS’s FA Score has 2 green FA rating(s).

  • CABA’s FA Score: 1 green, 4 red.
  • GHRS’s FA Score: 2 green, 3 red.
According to our system of comparison, GHRS is a better buy in the long-term than CABA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CABA’s TA Score shows that 4 TA indicator(s) are bullish while GHRS’s TA Score has 4 bullish TA indicator(s).

  • CABA’s TA Score: 4 bullish, 3 bearish.
  • GHRS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CABA is a better buy in the short-term than GHRS.

Price Growth

CABA (@Biotechnology) experienced а -4.94% price change this week, while GHRS (@Biotechnology) price change was +1.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.02%. For the same industry, the average monthly price growth was -18.10%, and the average quarterly price growth was -15.28%.

Reported Earning Dates

CABA is expected to report earnings on Nov 09, 2026.

GHRS is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-1.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CABA
Daily Signal:
Gain/Loss:
GHRS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

CABA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CABA has been loosely correlated with CGEM. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CABA jumps, then CGEM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CABA
1D Price
Change %
CABA100%
-4.35%
CGEM - CABA
49%
Loosely correlated
+0.40%
NCEL - CABA
47%
Loosely correlated
+8.43%
RAPP - CABA
45%
Loosely correlated
-14.67%
FATE - CABA
43%
Loosely correlated
+0.49%
AURA - CABA
42%
Loosely correlated
-1.52%
More

GHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GHRS has been loosely correlated with STTK. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if GHRS jumps, then STTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GHRS
1D Price
Change %
GHRS100%
-1.33%
STTK - GHRS
43%
Loosely correlated
-4.45%
FDMT - GHRS
38%
Loosely correlated
-3.66%
IMRX - GHRS
38%
Loosely correlated
+0.27%
CABA - GHRS
38%
Loosely correlated
-4.35%
CGEN - GHRS
37%
Loosely correlated
-0.93%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OPY101.971.31
+1.30%
Oppenheimer Holdings
NUE264.543.04
+1.16%
Nucor Corp
ZONE0.09N/A
N/A
CleanCore Solutions
KLAR13.12-0.03
-0.23%
Klarna Group plc
ELMD27.32-0.12
-0.44%
Electromed